Thursday, July 9, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ERNA”

213 pharma patents match "ERNA" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 213
Index total 30,257
Page 4 / 9

Quick answer

This filtered view shows 213 pharmaceutical patents matching "ERNA" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

213 results for “ERNA” · 30,257 patents in full index Clear search

  1. US 10266825

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  2. US 10259780

    Treatment of cataplexy

    Jazz Pharmaceuticals International III Limited · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted
  3. US 10233235

    Modulating the alternative complement pathway

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted
  4. US 10214553

    Solid state forms of sofosbuvir

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  5. US 10195151

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    Jazz Pharmaceuticals International III Limited · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  6. US 10188648

    Solid state forms of selexipag

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  7. US 10105341

    Treatment for obesity

    Jazz Pharmaceuticals International III Limited · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  8. US 9988603

    Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions

    Stem Cell & Regenerative Medicine International · Granted Jun 5, 2018 · Expires May 31, 2038

    granted
  9. US 9896502

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  10. US 9890210

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  11. US 9890211

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  12. US 9884908

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  13. US 9884907

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  14. US 9814706

    Hydrobromide salt of pridopidine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2017 · Expires Nov 9, 2037

    granted
  15. US 9796673

    L-tartrate salt of pridopidine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted
  16. US 9789057

    Pharmaceutical delivery system

    Perrigo Pharma International Designated Activity Company · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted
  17. US 9763904

    Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  18. US 9737560

    Process for preparation of a humic substance based gel for targeted external application

    BlackBalm, LLC · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  19. US 9730972

    Skin tightening lotion

    Ashley Diana Black International Holdings, LLC · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  20. US 9708610

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  21. US 9707270

    Method for administering ω-conopeptide

    Jazz Pharmaceuticals International III Limited · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  22. US 9687441

    Compositions for use with a fascia tissue treatment device to reduce cellulite

    Ashley Diana Black International Holdings, LLC · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted
  23. US 9682033

    Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  24. US 9649291

    Treatment for obesity

    Jazz Pharmaceuticals International III Limited · Granted May 16, 2017 · Expires May 11, 2037

    granted